Japan's Astellas has agreed to carry out clinical trials of a vaccine for serious diarrhoeal diseases which does not need to be refrigerated or injected and is produced in transgenic rice plants.
Boehringer Ingelheim has licensed a microbial expression technology from Vectron Biosolutions for use with its own molecules and for customers through its CMO business.
Intercell has killed development of its Travellers’ Diarrhoea Vaccine Patch after the product failed in clinical trials which will lead to job cuts and a dramatic reduction of R&D expenses.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
Wacker Chemie AG has expanded its biologics production facility, adding GMP manufacturing capacity and a process development building in response to customer demand.
Basel-headquartered Roche has paid fellow Swiss firm Lonza $290m (€203m) for its Singapore biologics plant in a bid to secure long-term manufacturing capacity for biotech cancer drugs.
Researchers have used plants from the tobacco family as a large-scale, cost-effective method of producing a HIV inhibitor, which could lead to the creation of a female controlled intervention to stop viral transmission.
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
US researchers have found a way to improve the yield of biopharmaceutical production by freeing up protein trapped in bacterial stores known as inclusion bodies.
US researchers have developed a chemoenzymatic strategy to synthesise the anticoagulant drug heparin and avoid the contaminant that has killed more than 80 people.
Tecan and GE Healthcare Life Sciences division are collaborating to
simplify high throughput (HT) protein purification by increasing
the speed and reliability of expression screening programmes.
Avecia Biologics has signed a development and manufacturing deal
with US firm BaroFold, making use of the company's protein
processing technology to produce its lead interferon-based multiple
sclerosis (MS) candidate.
New research has shown that silica nanowires can be used to deliver toxic agents into both human and bovine epithelial cell lines, opening up new options for drug targeting and delivery.
The Biologics division of UK company Avecia has launched pAVEway, a
new microbial system for producing high yields of a wide range of
therapeutically active protein, such as vaccines, cytokines and
growth factors.
Caprion and Ecopia have agreed to merge as equals to form an as yet
unnamed public entity with three programs in cancer and infectious
diseases in clinical development.
UK Biopharma company Evolutec has signed a deal with Wacker Biotech
to produce Evolutec's new autoimmune disease drug candidate rEV576
for clinical trials.
A simpler and more cost-effective way of obtaining high yields of
antibody fragments, which are used for research, diagnostic and
therapeutic applications may be possible after a deal was agreed to
produce the fragments in research...
Wacker-Chemie is to acquire German biotechnology company ProThera,
based in Jena, to boost its presence in the biologics manufacturing
sector. ProThera will now operate as Wacker Biotech.
In-Pharmatechnologist.com's periodic round-up of pharma production
developments from around the world sees Cognis mulling the sale of
process chemicals, Perrigo buying a generics and API manufacturer
and two new contract manufacturing...
German contract manufacturer Strathmann Biotec has won a contract
to manufacture clinical supplies a new type of cancer treatment in
development at Sweden's Active Biotech.
